- Last sale
- Nov 12, 2026 · -0.29%
- Market cap
- $124.30B
- 115.46M shares
- Filings
- 1,060
Q2 2027+12.4% FY26 yoy
Q2 2027+44.5% FY26 yoy
Q2 2027+40.5% FY26 yoy
Q2 2027derived+3.1% FY26 yoy
Q2 2027+49.2% FY26 yoy
Q2 2027−30.2% FY26 yoy
- $124.30B
- 26.4×
- 0.3×
- —
- 5.72%
- 0.32%
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2026 | 2026-03-31 | $403,430,000,000 | reported | |
| FY 2025 | 2025-03-31 | $359,051,000,000 | reported | |
| FY 2024 | 2024-03-31 | $308,951,000,000 | reported | |
| FY 2023 | 2023-03-31 | $276,711,000,000 | reported | |
| FY 2022 | 2022-03-31 | $263,966,000,000 | reported | |
| FY 2021 | 2021-03-31 | $238,228,000,000 | reported | |
| FY 2020 | 2020-03-31 | $231,051,000,000 | reported | |
| FY 2019 | 2019-03-31 | $214,319,000,000 | reported | |
| FY 2018 | 2018-03-31 | $208,357,000,000 | reported | |
| FY 2017 | 2017-03-31 | $198,533,000,000 | reported | |
| FY 2016 | 2016-03-31 | $190,884,000,000 | reported | |
| FY 2015 | 2015-03-31 | $179,045,000,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2026 | $381.00M | $4.75B | $5.13B | $3.17 | 120.20M sh | −3.9% | 89.7% |
| FY2025 | $345.00M | $3.15B | $3.49B | $2.75 | 125.11M sh | −3.7% | 62.9% |
| FY2024 | $314.00M | $3.03B | $3.34B | $2.40 | 129.99M sh | −4.1% | 86.0% |
| FY2023 | $292.00M | $3.64B | $3.93B | $2.09 | 135.60M sh | −6.7% | 82.4% |
| FY2022 | $277.00M | $3.52B | $3.79B | $1.83 | 145.37M sh | −8.1% | 93.7% |
Segments
Segments
LineFY2026ShareChange
North American Pharmaceutical$336.65B83%+10.6%
Oncology & Multispecialty$48.42B12%+31.4%
Medical-Surgical Solutions$11.51B2.9%+1.1%
Prescription Technology Solutions$5.81B1.4%+11.3%
International———
U.S. Pharmaceutical———
Total$403.43B
Wholesale drugs, proprietaries & druggists’ sundries
McKesson Corp is the largest of the 11 covered companies the SEC files under this code, by revenue. SIC 5122
CompanyRevenueGrowthNet marginMarket cap
MCKMcKesson Corp (this company)$403.4B12.4%1.2%$124.3B
CORCencora, Inc.$321.3B9.3%0.5%$66.7BCAHCardinal Health Inc$254.2B14.2%0.7%$64.3BHLFHerbalife Ltd.$5.0B0.9%4.5%$1.6BNUSNU Skin Enterprises, Inc.$1.5B14.3%10.8%$195.7MCOSMCosmos Health Inc.$65.3M19.9%29.3%$20.8MMEDSDataMeds AI, Inc.$23.3M28.7%433.9%$2.7MSTEKStemtech Corp$2.9M43.1%140.7%$1.6MESYNEnerSyn Global Inc.$866.9K30.8%303.4%$12.1MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
McKesson Corp · CIK 927653 · Engraved from SEC EDGAR